In medical therapies involving multiple stages, a physician's choice of a subject's treatment at each stage depends on the subject's history of previous treatments and outcomes. The sequence of decisions is known as a dynamic treatment regime or treatment policy. We consider dynamic treatment regimes in settings where each subject's final outcome can be defined as the sum of longitudinally observed values, each corresponding to a stage of the regime. Q-learning, which is a backward induction method, is used to first optimize the last stage treatment then sequentially optimize each previous stage treatment until the first stage treatment is optimized. During this process, model-based expectations of outcomes of late stages are used in the optimization of earlier stages. When the outcome models are misspecified, bias can accumulate from stage to stage and become severe, especially when the number of treatment stages is large. We demonstrate that a modification of standard Q-learning can help reduce the accumulated bias. We provide a computational algorithm, estimators, and closed-form variance formulas. Simulation studies show that the modified Q-learning method has a higher probability of identifying the optimal treatment regime even in settings with misspecified models for outcomes. It is applied to identify optimal treatment regimes in a study for advanced prostate cancer and to estimate and compare the final mean rewards of all the possible discrete two-stage treatment sequences.
Introduction
A dynamic treatment regime is a mathematical formalism for what physicians do routinely when making therapeutic decisions sequentially. The physician chooses a first treatment using diagnostic information, administers it, and observes the patient's response. A second decision is based on the diagnostic information, first treatment, and newly observed response. This process may be continued, using the patient's history up to the current stage for each decision, until either a satisfactory outcome is achieved or no further treatment is considered acceptable. The dynamic treatment regime is the sequence of decision rules embedded in the sequence of alternating observations and treatments.
Methods for evaluating dynamic treatment regimes have been used increasingly for patients undergoing long-term care involving multi-stage therapies. It is challenging to identify optimal decision rules in such multi-stage treatment settings because of the complicated relationships between the alternating sequences of observed outcomes and treatments. The decision at each treatment stage depends on all observed historical data and influences all future outcomes and treatments. In turn, outcomes at each stage are affected by all previous treatments and influence all future treatment decisions. It is well known that simply optimizing the immediate outcome of each stage, which is called a myopic or greedy optimization, may not achieve the best final outcome. Simulation studies in Section 3 demonstrate this point.
Despite these complications, many approaches have been proposed to identify, estimate, or optimize of being observed (positivity). To identify the optimal action at each stage of backward induction, the estimated reward is computed for each possible action assuming that the actions at all future stages will be optimal. This is performed by fitting a parametric model for the counterfactual future reward as a function of actions and current history. The final cumulative reward is the estimate of what the patient's total reward would be if all actions were optimal. In the sequel, we will use the terms 'payoff' and 'reward' interchangeably to mean the same thing.
Notation and method
For each subject i = 1, · · · , n and stage s = 1, · · · , K, where n denotes the sample size and K denotes the total number of multiple stages, let Z i,s denote the time-dependent covariates measured at the beginning of s-th stage, A i,s , the treatment or action, and Y i,s , the observed outcome. 
where each A i,j is conditional on all the historic information observed prior to stage j, including previous treatments and responses. For simplicity, we have suppressed conditional notation. In words, this equation says that 's are random variables, rather than mean functions as denoted by other authors.
We next define Δ i,s to be the total future loss from stages s to K if action A i,s is taken instead of A i,s , while all actions from stage s + 1 to K are optimal. Thus, if A i,s = A i,s , then Δ i,s = 0, whereas if A i,s is not optimal, then Δ i,s > 0. This Δ i,s is essentially Murphy's regret function [6] . Robins defined a similar blip function by comparison with a 'zero' treatment instead of the optimal one [5] . We use the counterfactual in (1) and loss Δ i,s to define the cumulative future reward to patient i, from stages s to stage K, for taking the optimal action from stage s onward as
The basic idea is that the reward R i,s is obtained from
by adding back the future loss due to taking a suboptimal action at stage s. For example, if Y i,s is the increment in survival time for stage s, then R i,s is the sum of the stagewise survival times from stage s onward associated with all current and future actions being optimal, given the past treatment and response history.
Given the aforementioned structure for the future reward R i,s at each stage s, the counterfactual cumulative outcome in Equation (1) can be written in the more compact form
Step 2. For the current step s,
Step 2.1 Fit the regression model (15) 
and thusQ
Step 2.2 Use the estimated causal effectsD i,s ( j, l) given by (16) to identify the estimated optimal actionÂ i,s = argmax 1⩽j⩽J s {max l≠jDi,s (j, l)}.
Step 2.3 Define the estimated future loss due to taking action
Step 2.4 By (2), step 2.3 gives the estimateR
Step 3.
, and go to Step 2.1 If s = 1, stop.
At the end of these steps,Â i,1 , · · · ,Â i,K , the optimal treatments for all subjects at all stages, have been identified, andR i,1 is the estimated total payoff from taking these estimated optimal actions. With this algorithm, the optimization is global rather than myopic or local.
Asymptotic properties of the estimators are given in Appendix B. The 'Sandwich' formula [33] is used to account for the extra variation because of plugging in an estimator from a late treatment stage into the regression models for an early stage.
Comparison with standard Q-learning
The method described previously is a robust modification of standard Q-learning [23, 28] . For all treatment stages except the last, to estimate counterfactual outcomes under optimal actions, standard Qlearning uses predicted values from previously fitted linear models plus estimated loss due to suboptimal actions. In contrast, our modified Q-learning method uses the values actually observed plus the estimated loss. Let 
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Standard Q-learning does backward induction using the same steps as our backward induction algorithm through step 2.3, but it uses the estimated stage K reward
.
In contrast, our estimated stage K reward iŝ
The difference is that standard Q-learning uses predicted valuesQ i,K obtained from a regression model, while our modified Q-learning method uses the observed values
. This difference is carried to the next stage,
Similar differences are accumulated during the iteration of this process in the backward induction steps from s = K − 1 to s = 1.
The modified Q-learning method has the following advantages. First, Q M i,s uses observed outcomes whenever possible for any s ⩽ K, whereas Q i,s uses model-based expectations for any s < K. Retaining the original outcomes helps the modified Q-learning rely less on the specification of the models used in (15) , and thus improves robustness. This is shown by our simulation study in the next section when the model (15) 
This means that the predicted reward under optimal treatment regimes for stage s + 1 onward is always at least the observed reward under the actual regimes, which may be suboptimal. This is a desirable property that does not always hold for standard Q-learning because, in practice, one may observe Q i,s < ∑ K j=s Y i for some s < K. This happens simply because, for some subjects, the predicted rewards under optimal treatment regimes for stage s + 1 onward are less than their observed actual reward. Furthermore, for s < K, if a patient has received the optimal treatment regimes for stage s + 1 onward, then with the modified Q-learning, because Δ i,r = 0 for all r ⩾ s + 1, the potential outcome under the treatment sequence
, the observed reward from stage s onward. This is in agreement with the 'consistency assumption'. This assumption, stated at the beginning of Section 2, requires that the assumed counterfactual outcomes under the actual observed actions must be equal to the observed outcomes. It is a very natural assumption and commonly required in causal inference [34] . In contrast, with standard Q-learning, Q i,s may not equal ∑ K r=s Y i,r , even if a patient receives the optimal treatment regimes for stage s + 1 onward. That is, as an estimate of the counterfactual outcome, Q i,s may violate the consistency assumption on individual basis, although it satisfies this assumption in expectation when the reward models are correctly specified. We will compare the performance of standard and modified Q-learning in the next section by simulation.
Simulation studies
The correct specification of reward models is very important for Q-learning [32] . In this section, we use simulations to show that, in some scenarios, when the reward models are misspecified, the modified Qlearning outperforms standard Q-learning. For simplicity, we evaluate two-stage treatment sequences. Sample sizes 50, 100, 200, and 400 are considered. We use three scenarios, each simulation scenario is replicated 1000 times.
Scenario I
In scenario I, we assume an unobserved variable V ∼ Normal(0, 2 2 ). 
for all subjects, the goal is to find the optimal two-stage treatment regimes that maximizes Y.
In this scenario, both treatments A 1 and A 2 are randomized. The optimal stage 2 treatment is A 2 = I(A 1 = 1). Then the reward for stage 2 under A 2 is
We assume the following model to optimize A 1 .
The true values for the aforementioned parameters are 1 = ( 10 , 11 ) T = (0.25, 0.5) T and 1 = ( 10 , 11 ) T = (0, −1) T . The optimal stage 1 treatment is A 1 = I(Z 1 < 0). If we use a myopic strategy to optimize A 1 by maximizing Y 1 = Z 1 (A 1 − 0.5) + V + 1 , we will obtain a wrong solution A 1 = I(Z 1 ⩾ 0). To apply the modified Q-learning, we first fit the following model, 
). Details about this derivation is provided in Appendix C. After fitting the above model to obtain̂2 and̂2, the estimated optimal stage 2 treatment iŝ
Then letR
with | ⋅ | denotes absolute value. We use the outcome Q M 1 to fit the model in (4). After estimatorŝ1 and 1 are obtained, the estimated optimal stage 1 treatment iŝ
The simulation results for samples of size 200 are given Tables I and II (each first panel from the left, scenario I). In general, the bias is small, and the empirical and asymptotic standard errors (SE and ASE) match well, with coverage probabilities of the 95% confidence intervals all close to nominal. The modified Q-learning correctly identified the optimal stage 1 and stage 2 treatments 91.1% and 88.4% of the time, respectively. Parameter estimations for other sample sizes (n=50, 100, or 400) are also performed well by the modified Q-learning (results not shown).
We apply standard Q-learning to the same data sets. Both standard and modified Q-learning fit the same regression models (5) for treatment stage 2. Naturally, they obtain exactly the same results for stage 2 (Table II) but differ for the stage 1 estimates (Table I) . As shown in Equation (7), the outcome used by the modified Q-learning is the actually observed values Y 2 plus the estimated loss due to suboptimal stage 2 actions. In contrast, the outcome used by standard Q-learning for stage 1 is the predicted valuê Y 2 from stage 2 by model (5) plus the same estimated loss, as follows.
Using Q 1 to replace Q M 1 in (4), the same linear regression model in (4) is fit to identify the optimal stage 1 treatments. Note that Q M 1 carries this information from V by using the original data Y 2 , but Q 1 discards this information by using the model based valueŶ 2 . Due to this difference, the two methods obtain different stage 1 estimates (Table I) . Standard Q-learning gives biased estimates for 11 and 11 . Consequently, the probability that it correctly identifies the optimal stage 1 treatments is only 38.2%, much lower than that achieved by the modified Q-learning (91.1%). In summary, standard Q-learning uses model-based values in the construction of counterfactual outcomes and is prone to bias introduced by Copyright model misspecification. As the number of treatment stages increases, the model-based values will be used more times during the backward induction, and this bias problem will become more severe. In contrast, the modified Q-learning achieves robustness against model misspecification by using the original data instead of model-based values whenever possible. Because the main goal of Q-learning is to correctly identify optimal treatments, we conducted additional simulations for a range of sample sizes and compared performance of modified Q-learning with standard Q-learning. We also compared their performances with the myopic strategy that uses Y 1 to optimize A 1 and Y 2 to optimize A 2 . Figure 1 shows these probabilities under a range of sample sizes. The modified Q-learning has larger probabilities than standard Q-learning to correctly identify the optimal stage 1 treatments. Both the modified and standard Q-learning have much better performances than the myopic strategy.
It is also interesting to note that in this setting with misspecified reward models, the optimal treatment selection power of the modified Q-learning increases with sample size, but this is not true for either standard Q-learning or myopic optimization. This shows that in situations of model misspecification, a large sample size cannot remedy a non-robust or incorrectly designed optimization algorithm and may even make things worse. Specifically in this simulation setting, because there are only two treatment options at each stage, a pure random selection of any one of them has a probability of 50% of being correct. The less than 50% power of standard Q-learning and myopic optimization shown in Figure 1 reveal that they are severely biased in such a situation with misspecified reward models. It also explains why their empirical power levels decrease with sample size. This is because their true power levels are less than 50% as n → ∞, and equal to 50% as n → 0 (equivalent to a pure random selection). Comparisons between the modified and standard Q-learning, myopic optimization, g-estimation and regret minimization: probability (power) of correctly identifying the optimal stage 1 and stage 2 treatments in scenarios I, II, and III. Note: For stage 1, in all scenarios, the power curves for the modified Q-learning, g-estimation and regret minimization almost overlap with each other. For stage 2, in all scenarios, the power curves for the modified and standard Q-learning and myopic optimization overlap with each other, so that only the solid curve (modified Q-learning) is visible; they almost overlap with those for g-estimation and regret minimization in scenarios I and II and are higher than those for g-estimation and regret minimization in scenario III.
Scenarios II and III, and other optimization methods
Treatments in scenario I are randomized. We also consider other treatment selection models. In scenario II, treatment assignment probabilities depend on observed covariates and outcomes, namely,
. In scenario III, treatment assignments further depend on the unobserved variable V, as in the succeeding texts,
All the other data generation mechanisms remain the same as in scenario I. The same data analyses shown in the previous subsection for scenario I by standard and modified Q-learning, and by the myopic optimization method, are also conducted for scenarios II and III. As suggested by a reviewer, we also compare the proposed estimator to the estimators by Murphy [6] and Robins [5] . Moodie et al. [25] provided a nice description of these estimators together with R functions for implementing them, which are used below with combination of her and our notations.
In our setting of data generation, the g-estimator [5] starts with the following estimation functions. Denote by j the observed history prior to A j , j = 1, 2. Let 1 ( 1 , a 1 S 1 (a 1 ) = a 1 (1, z 1 
Also assume treatment selection models as follows:
The aforementioned resulting estimator̂is used in the following estimating equation to estimate and then find out the optimal treatment regimes
Murphy [6] defined a regret function as the loss due to taking a suboptimal action. In the above setting, the regret functions for the two stages can be written
. If an optimal action is taken, that is, a j = d j ( j ), then the regret is zero, namely, j ( j , a j ) = 0. The true regret functions are 1 ( 1 , a 1 ) = |z 1 |I{a 1 ≠ I(z 1 < 0)} and 2 ( 2 , a 2 ) = |a 1 − 0.5|I(a 2 ≠ a 1 ). Using the methods proposed by Murphy [6] and also adopted by Moodie et al. [25] , logistic functions as the following are used to approximate these piecewise linear functions *
The true values of the above s are the same as that for the g-estimation.
For all the methods, the parameter estimates and their empirical and asymptotic standard errors are reported in Tables I and II . The standard and modified Q-learning and the myopic optimization use more parameters for their outcome models (both s and s), whereas the g-estimation and regret minimization use less parameters for their outcome models (only the s). However, they use logistic regression models for treatment selection, for which the estimated parameters are not reported. Similarly, as Moodie et al. [25] , the bootstrap method (200 randomly drawn samples from the original data with replacement) are used to compute the asymptotic standard errors for the g-estimation and regret minimization. In the aforementioned tables, standard Q-learning estimators show substantial bias for the stage 1 parameters 11 and 11 in all the three scenarios. The modified Q-learning, g-estimation and regret minimization have only very small bias in scenarios I and II, but some bias in scenario III, in which both the outcome and treatment assignment models are misspecified.
The power levels for all the methods to correctly identify the optimal treatments are depicted in Figure 1 . For stage 1, in all three scenarios, the modified Q-learning, g-estimation and regret minimization perform almost the same, whereas the myopic optimization and standard Q-learning have poor performance. For stage 2, the standard and modified Q-learning, and the myopic optimization have the same performance. Comparing with them, the g-estimation and regret minimization have slightly lower power levels in scenario III, but the same power levels in scenarios I and II. In this figure, the case of n = 50 for g-estimation is not shown because it involves singular matrices and other computation issues. Copyright 
Application to a prostate cancer study
We applied the modified Q-learning to analyze data from a clinical trial of advanced prostate cancer conducted at MD Anderson Cancer Center from 1998 to 2006 to evaluate multi-stage therapeutic strategies [17, 19] . One hundred and fifty patients with advanced prostate cancer were randomized at enrollment to receive one of four chemotherapy combinations, abbreviated as CVD, KA/VE, TEC, and TEE, during an initial treatment period of 8 to 24 weeks. Thereafter, response-based assignment to the second stage treatment was made. Patients with a favorable response to the initial treatment stayed on the same treatment during the second stage ('respond  → stay'), while patients who did not have a favorable response were randomized among the three remaining treatments ('no response  → switch'). Because 47 patients did not follow this protocol because of severe toxicities or progressive disease or other reasons, Wang et al. [17] defined viable dynamic treatment regimes including such discontinuation and accounting for both efficacy and toxicity. This evaluation was based on expert score defined from the bivariate outcomes of efficacy and toxicity in each stage. The scores for the first and second stages were denoted by Y 1 and Y 2 , respectively. It was further specified that patients who went off treatment during the first stage received a score of Y 2 = 0 for stage 2. We used the modified Q-learning to identify the optimal treatments for the two stages that maximized
The data set included the following covariates: patient age, radiation treatment (yes or no), length of time hormone therapy was received (in months) before registration, location of evidence of disease at enrollment, strata (low or high risk), baseline prostate-specific antigen level, and alkaline phosphatase hemoglobin concentrations.
Stage 2 estimation
By design, patients with a favorable response in stage 1 had that treatment repeated, and we assumed that they received the optimal A 2 . Because patients whose first stage treatment failed were re-randomized, this produced a saturated factorial design with 12 different two-stage treatment sequences. Because of the limited sample size, we fit a model with 12 indicators for the 12 treatment sequences, without including their interactions with patients' characteristics. The fitted model showed that for patients who received TEC in stage 1 and did not have a favorable response, the best stage 2 treatment was CVD. For patients who did not receive TEC in stage 1 and did not have a favorable response, the best stage 2 treatment was TEC. The computation of potential stage 2 scores under the aforementioned optimal stage 2 treatment is shown in Table III . If the stage 1 treatment failed, the score indicated in Table III is added to each patient's actual stage 2 score, Y 2 , to obtain a hypothetical optimal score, R 2 , which is used in the next step of the analysis. For patients who had a favorable response in stage 1 treatment, we set R 2 = Y 2 . For patients who went off treatment during the first stage, because they did not receive any stage 2 treatment, they could not be used in the estimation of stage 2 treatment effects. They were still included in the analyses for stage 1 and overall outcomes by assigning R 2 = 0. This had an impact on the interpretation of the identified optimal regimes, as shown in the next subsection.
Stage 1 estimation
After the stage 2 estimation, we defined
For the four stage 1 treatments, we fit a linear regression model for all main effects and interactions associated with the stage 1 treatment with response Q M 1
. All covariates mentioned at the beginning of this Section 4 were considered. Using the Akaike information criterion (AIC) to conduct a stepwise variable selection, we found that age seemed to be the only significant covariate. Interactions between age and treatments were not statistically significant. Age was centered at 65 years, which is roughly the mean. The fitted model given in Tables III and IV shows that the stage 1 treatment may be ranked in the following order: TEC, KA/VE, TEE, and CVD, and they roughly can be put into two groups, {TEC, KA/VE} and {TEE, CVD}, with substantial difference between the groups, but not much difference within either group. Combining these results with those in Table III , which show the optimal stage 2 treatment conditional on stage 1 treatment, we conclude that the optimal treatment sequence (strategy) for these patients is as follows. Start with initial treatment TEC. If a patient achieves a favorable response, then continue to treat with TEC in the second stage. Otherwise, that is, if a patient does not achieve a favorable response to the initial treatment, then treat with CVD in the second stage. We denote this regime by (TEC, CVD). Other regimes are denoted similarly. The estimates in Table IV are not for stage 1 outcomes only, but rather for the mean final rewards if the stage 2 treatments had been optimized conditional on the stage 1 treatment. For example, compared with CVD, the initial treatment TEC could have improved mean final outcome score by 0.2757 (standard deviation = 0.1294), if all subjects had received their respective optimal stage 2 treatments conditional on their stage 1 treatments. Referring to Table III, the optimal two-stage treatment strategy is (TEC, CVD) for subjects who receive TEC in stage 1, and is (CVD, TEC) for subjects whose stage 1 treatments are CVD. The noted difference of 0.2757 in Table IV between initial treatments TEC and CVD is actually the difference between the two regimes (TEC, CVD) and (CVD, TEC). This difference is statistically significant (p = 0.033).
Estimation for the mean rewards of 16 regimes
Similar to standard Q-learning, the modified Q-learning does not require fully specified reward functions for all possible treatment strategies. For the aforementioned example, combining the results in Tables III  and IV , we have estimated the mean rewards of the following four regimes: (TEC, CVD), (KA/VE, TEC), (TEE, TEC), and (CVD, TEC). However, we have not obtained estimates for other regimes, for example, (TEC, TEE). There are 12 such regimes. This might be viewed as an inconvenience for Q-learning or the modified Q-learning. One may try to introduce some extra models to estimate the mean rewards for the other 12 regimes. However, we show in the succeeding discussions that this is unnecessary.
In Table III , our purpose was to identify the optimal regimes, thus we used the optimal stage 2 treatments as references and computed the potential loss Δ 2 due to not taking the optimal stage 2 treatment. When our purpose is to compute mean final rewards for other regimes rather than identifying optimal regimes, we replace those optimal stage 2 treatments in Table III by the treatments for which we intend to estimate and use them as the new references. Then we figure out the new potential loss (or gain) Δ ′ 2 due to not taking the new reference treatments in stage 2 and compute the final reward values for regimes using the new reference treatments in stage 2. We put these Δ ′ 2 values in Table V . For convenience, we copy Table III to the top of Table V. The middle part of Table V Tables III and V are intended to be used for patients who had an unfavorable stage 1 response; consequently, their diagonal elements are not given because of the trial design that only those patients who achieved a successful stage 1 response could receive a stage 2 treatment same as stage 1. The results for 12 possible regimes are shown in Figure 2 . For this particular example, standard Q-learning gives very similar results (not shown). An advantage of both standard and modified Q-learning is that they can identify optimal dynamic treatment regimes for each individual. This can be performed by including interactions between individual level covariates and treatments. For example, if in the aforementioned analysis we include an interaction between patient age and stage 1 treatment, then we can identify the age-specific optimal treatment regimes. If we include an interaction between stage 1 score and stage 2 treatment in the model in Section 4.1, then such an identified optimal stage 2 treatment will depend on stage 1 score. These are all desirable explorations to maximize benefit for each patient. However, because of the limited sample size, this may not yield stable results and thus is not presented here.
Recall that for patients who went off treatment during stage 1 because of toxicity or progressive disease, and thus did not receive any stage 2 treatment, we set R 2 = 0. By doing this, all 150 patients were included in the aforementioned analyses. This practical modification of the original treatment plan is consistent with the idea of 'viable treatment regimes' of Wang et al. [17] . For example, a patient received TEC as in stage 1, then went off treatment because of toxicity or progressive disease or other reasons and did not receive any stage 2 treatment, the data from this patient are used in the estimation of final reward for three regimes, namely, (TEC, CVD), (TEC, KA/VE), and (TEC, TEE).
Discussion
We have demonstrated a robust modification of Q-learning for optimizing a multi-stage treatment sequence in settings where the payoff is a cumulative outcome, and intermediate values at each stage are available. The modified Q-learning preserves more randomness in the observed outcomes, and thus is more robust against model misspecification, has higher power to identify optimal treatments, and satisfies the consistency assumption. If the treating physician happens to adopt the treatment regime that is optimal for a given patient's condition, the optimal outcome assumed by the modified Q-learning is precisely the observed outcome.
Optimization of a K-stage treatment regime is difficult, because conditioning on the treatment history can result in very complicated models. This is a common problem with all optimization algorithms for multi-stage treatments [5, 6] . We handle this problem by making a Markov assumption. This kind of assumption also was used in others' simulation studies [6] . In reality, this assumption may be violated. The degree of robustness of model results against this assumption is unknown. In such a case, if sample size permits, it is best to explore models without this Markov assumption, that is, include a large number of interaction terms to involve earlier stage history into the reward models. In cancer research, practical values for K are about 2 to 5, corresponding to disease recurrences. In other areas of application where the value of K may be much larger, the advantages of the modified Q-learning, that is, satisfying the consistency assumption and being robust against model misspecifications, may become more prominent.
An attractive feature of both standard and the modified Q-learning is that they do not need model treatment selection probabilities. Most other methods require this additional structure, including the history-adjusted marginal structural models [35] and A-learning [6] . There are very subtle arguments required with the use of modeling treatment selections. It has been argued that small misspecifications in such selection models can accumulate over treatment stages and thus cause severe bias and convergence problems [36] . Therefore, there is an advantage to avoid using such treatment selection models.
where
) T is the stage 2 design matrix and
With this optimized outcome at stage 2, the potential cumulative outcome, given S 1,i , A 1,i , and
After this, we estimate the first stage parameters bŷ
The asymptotic properties of these parameter estimates are presented in the succeeding discussions, under the following technical conditions. ) T , minimizes
and the true value for 1 , denoted by 10 = ( T
10
, T 10 ) T , minimizes
where  0 = lim n P n denotes the true probability measure. We assume that the limit exists and is finite in the aforementioned expressions.
is at least twice continuously differentiable with respect to k , and the Hessian matrix,
exists and is positive-definite. (A3) With probability one, Pr
Condition A1 says that 10 and 20 are true values that minimize loss function in each step. If Q k takes the form of the linear model (17) , condition A2 is equivalent to non-singularity of the design matrix
) T for k = 1, 2. From condition A3, we assume there is no possibility of non-regularity.
In case of Pr(
T k S k2 = 0) > 0, it has been verified that multi-stage estimation, including standard Qlearning, may be biased and the aforementioned asymptotic properties may be inappropriate, and thus requiring special treatment [13, 37] . Here, we do not consider such complications.
Denote the estimating equation for 2 as
Theorem 1
Under conditions A1-A3,
Proof
It is a direct application of the 'Sandwich' formula [33] , so omitted.
Because the estimation of 1 depends on̂2, let Ψ 2,2 denote the sub-equation of Ψ 2 , and D 2,2 denote the sub-matrix of D 2 , both corresponding to 2 at 2 = 20 .
, where 20 and 20 are true values of 2 and 2 .
The estimating equation for 1 is
Theorem 2
where V 1 ( 10 , 20 ) can be estimated bŷ
Proof Again, it is a direct application of the 'Sandwich' formula [33] , so omitted.
Appendix C: simulation model
In general, suppose we have random variables X 1 , · · · , X p , and Y, and we would like to do regression of
In Section 3, we have
We use the following model to do regression analysis.
To find out the true values for s in the aforementioned model, we consider regressing Y 2 on the following orthogonal set of random variables {1,
That is to say, we consider the model
By using the formula
mentioned at the beginning of this Appendix, we obtain
For the aforementioned coefficients, the only one that is not straightforward is Then the conditional optimal treatment is just the one that maximize the mean reward in stage 3, which is mathematically described aŝ
Then we estimate the potential optimal reward R 3 in stage 3 each individual would have achieved had he/she received his/her conditional optimal treatment as indicated previously. If an individual actually received his/her conditional optimal treatment, the estimated rewardR 3 is set to be the observed Y 3 by our modified Q-learning. Otherwise,R 3 is set to be Y 3 plus the difference between the rewards for the optimal and actual treatments. Then find out the optimal stage 2 treatment conditional on current covariates Z 2 , previous treatment A 1 and outcome Y 1 , as below. 
The potential total reward from stage 2 onwards (i.e., sum of rewards from stages 2 and 3), R 2 , had a subject received his optimal stage 2 treatment and his corresponding optimal stage 3 treatment, can be estimated as follows: This will give estimates for the optimal treatment stage 1 treatments conditional on Z 1 as follows:
Under this optimal stage 1 treatment and corresponding optimal stages 2 and 3 treatments, the total optimal reward is R 1 , which can be estimated bŷ
The aforementioned procedures are to derive the optimal treatments using a backward induction. After the estimation results are obtained, to apply them in practice, the optimal treatment decision rules are determined as follows. First use (21) to find out the optimal treatment conditional on covariate Z 1 . Suppose this gives A 1 = 1. After receiving this treatment A 1 = 1, the observed stage 1 outcome is Y 1 . At the beginning of stage 2, covariate Z 2 is observed. Then at this moment, the optimal stage 2 treatment can be determined by (20) based on Z 2 , A 1 = 1 and the observed Y 1 . Suppose the optimal treatment conditional on these variables is A 2 = 3. After receives this treatment A 2 = 3, the observed stage 2 outcome is Y 2 . At the beginning of stage 3, covariate Z 3 is observed. At this time, the optimal stage 3 treatment is determined by (19) 
